Experimental Drug Shows Activity Against Advanced Ovarian Cancer in Phase II Trial

Ob Gyn News ◽  
2007 ◽  
Vol 42 (13) ◽  
pp. 2
Author(s):  
PATRICE WENDLING
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Experimental Drug

Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study

1994 ◽  
Vol 30 (7) ◽  
pp. 911-914 ◽  
Author(s):  
S Tumolo ◽  
B Ramanath Rao ◽  
M.E van der Burg ◽  
J.P Guastalla ◽  
J Renard ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Gynaecological Cancer ◽  
Cooperative Group

Topotecan and paclitaxel in second line treatment of advanced ovarian cancer (AOC): a gineco phase II trial

2001 ◽  
Vol 37 ◽  
pp. S324
Author(s):  
M. Fabbro ◽  
B. Leduc ◽  
L. Mignot ◽  
P. Ayela ◽  
D. Assouline ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Line Treatment ◽  
Second Line

Topotecan (T) and cyclophosphamide (CY) in second line treatment of advanced ovarian cancer (AOC): a gineco phase II trial

2001 ◽  
Vol 37 ◽  
pp. S324
Author(s):  
F. Mayer ◽  
P.Y. Peaud ◽  
J.D. Tigaud ◽  
M.C. Kaminsky ◽  
S. Culine ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Line Treatment ◽  
Second Line

scholarly journals Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

2020 ◽  
Vol 8 (1) ◽  
pp. e000829 ◽  
Author(s):  
Dmitriy Zamarin ◽  
Sven Walderich ◽  
Aliya Holland ◽  
Qin Zhou ◽  
Alexia E Iasonos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cell ◽  
Phase Ii ◽  
Clinical Benefit ◽  
Overall Response Rate ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Folate Receptor ◽  
Advanced Ovarian Cancer ◽  
Cell Responses

BackgroundImmune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an attractive target for a combination immunotherapy to potentially overcome resistance to ICI in OCs. The current study sought to examine clinical and immunologic responses to TPIV200, a multiepitope FRα vaccine administered with programmed death ligand 1 (PD-L1) inhibitor durvalumab in patients with advanced platinum-resistant OC.MethodsFollowing Simon two-stage phase II trial design, 27 patients were enrolled. Treatment was administered in 28-day cycles (intradermal TPIV200 and granulocyte-macrophage colony-stimulating factor (GM-CSF) for 6 cycles and intravenous durvalumab for 12 cycles). Primary endpoints included overall response rate and progression-free survival at 24 weeks. Translational parameters focused on tumor microenvironment, PD-L1 and FRα expression, and peripheral vaccine-specific immune responses.ResultsTreatment was well tolerated, with related grade 3 toxicity rate of 18.5%. Increased T cell responses to the majority of peptides were observed in all patients at 6 weeks (p<0.0001). There was one unconfirmed partial response (3.7%) and nine patients had stable disease (33.3%). Clinical benefit was not associated with baseline FRα or PD-L1 expression. One patient with prolonged clinical benefit demonstrated loss of FRα expression and upregulation of PD-L1 in a progressing lesion. Despite the low overall response rate, the median overall survival was 21 months (13.5–∞), with evidence of benefit from postimmunotherapy regimens.ConclusionsCombination of TPIV200 and durvalumab was safe and elicited robust FRα-specific T cell responses in all patients. Unexpectedly durable survival in this heavily pretreated population highlights the need to investigate the impact of FRα vaccination on the OC biology post-treatment.

Sign in / Sign up

Export Citation Format

Share Document